Detection and analysis of signals of adverse events of memantine based on the US food and drug administration adverse event reporting system

References

• Handa M, Sanap SN, Bhatta RS, et al. Combining donepezil and memantine via mannosylated PLGA nanoparticles for intranasal delivery: characterization and preclinical studies. Biomater Adv. 2023;154:213663. doi: 10.1016/j.bioadv.2023.213663
   PubMedGoogle Scholar
• Ulep MG, Saraon SK, McLea S. Alzheimer Disease. J Nurse Practit. 2018;14(3):129–135. doi: 10.1016/j.nurpra.2017.10.014
   Google Scholar
• Y YJ, Waldvogel HJ, FR M, et al. iGluR expression in the hippocampal formation, entorhinal cortex, and superior temporal gyrus in Alzheimer’s disease. Neural Regen Res. 2022;17(10):2197–2199. doi: 10.4103/1673-5374.335804
   PubMed Web of Science ®Google Scholar
• Conway ME. Alzheimer’s disease: targeting the glutamatergic system. Biogerontology. 2020;21(3):257–274. doi: 10.1007/s10522-020-09860-4
   PubMed Web of Science ®Google Scholar
• Painuli S, Semwal P, Zam W, et al. NMDA inhibitors: a potential contrivance to assist in management of Alzheimer’s disease. Comb Chem High Throughput Screen. 2023;26(12):2099–2112. doi: 10.2174/1386207325666220428112541
   PubMed Web of Science ®Google Scholar
• Kabir MT, Sufian MA, Uddin MS, et al. NMDA receptor antagonists: repositioning of memantine as a multitargeting agent for Alzheimer’s therapy. Curr Pharm Des. 2019;25(33):3506–3518. doi: 10.2174/1381612825666191011102444
   PubMed Web of Science ®Google Scholar
• Lu B, Xian X. Study on correlation between glutamate and Alzheimer’s disease Chinese. J Coal Int Med. 2023;26(2):220–224.
   Google Scholar
• Handa M, Sanap SN, Bhatta RS, et al. Simultaneous intranasal codelivery of donepezil and memantine in a nanocolloidal carrier: optimization, pharmacokinetics, and pharmacodynamics studies. Mol Pharm. 2023;20(9):4714–4728. doi: 10.1021/acs.molpharmaceut.3c00454
   PubMedGoogle Scholar
• Dementia: assessment, management and support for people living with dementia and their carers. London: National Institute for Health and Care Excellence (NICE); 2018.
   Google Scholar
• Shumar J, Ordway S, Junga Z, et al. Memantine-induced liver injury with probable causality as assessed using the Roussel uclaf causality assessment method (RUCAM). ACG Case Rep J. 2019;6(8):e00184. doi: 10.14309/crj.0000000000000184
   PubMed Web of Science ®Google Scholar
• Tian X, Chen L, Gai D, et al. Adverse event profiles of PARP inhibitors: analysis of spontaneous reports submitted to FAERS. Front Pharmacol. 2022;13:851246. doi: 10.3389/fphar.2022.851246
   PubMed Web of Science ®Google Scholar
• Lane CA, Hardy J, Schott JM. Alzheimer’s disease. Eur J Neurol. 2018;25(1):59–70. doi: 10.1111/ene.13439
   PubMed Web of Science ®Google Scholar
• Rammes G, Danysz W, Parsons CG. Pharmacodynamics of memantine: an update. Curr Neuropharmacol. 2008;6(1):55–78. doi: 10.2174/157015908783769671
   PubMed Web of Science ®Google Scholar
• Dong H, Wu S, Hu N, et al. Efficacy of tenuigenin and β-asarone as augmentations for memantine in the treatment of Alzheimer’s disease. Neuroreport. 2018;29(3):203–207. doi: 10.1097/WNR.0000000000000952
   PubMed Web of Science ®Google Scholar
• Xiong J, Kang SS, Wang Z, et al. FSH blockade improves cognition in mice with Alzheimer’s disease. Nature. 2022;603(7901):470–476. doi: 10.1038/s41586-022-04463-0
   PubMed Web of Science ®Google Scholar
• Abd-Elrahman KS, Albaker A, de Souza JM, et al. Aβ oligomers induce pathophysiological mGlur5 signaling in Alzheimer’s disease model mice in a sex-selective manner. Sci Signal. 2020;13(662):eabd2494. doi: 10.1126/scisignal.abd2494
   PubMed Web of Science ®Google Scholar
• Jiang J, Jiang H. Efficacy and adverse effects of memantine treatment for Alzheimer’s disease from randomized controlled trials. Neurol Sci. 2015;36(9):1633–1641. doi: 10.1007/s10072-015-2221-2
   PubMed Web of Science ®Google Scholar
• Yang Z, Zhou X, Zhang Q. Effectiveness and safety of memantine treatment for Alzheimer’s disease. J Alzheimers Dis. 2013;36(3):445–458. doi: 10.3233/JAD-130395
   PubMed Web of Science ®Google Scholar
• Borges LG, Bonakdarpour B. Memantine-induced chorea and dystonia. Pract Neurol. 2017;17(2):133–134. doi: 10.1136/practneurol-2016-001470
   PubMedGoogle Scholar
• Hanagasi HA, Tufekcioglu Z, Emre M. Dementia in Parkinson’s disease. J Neurol Sci. 2017;374:26–31. doi: 10.1016/j.jns.2017.01.012
   PubMed Web of Science ®Google Scholar
• Zhou T, Wang J, Xin C, et al. Effect of memantine combined with citalopram on cognition of BPSD and moderate Alzheimer’s disease: A clinical trial. Exp Ther Med. 2019;17(3):1625–1630. doi: 10.3892/etm.2018.7124
   PubMed Web of Science ®Google Scholar
• Nakamura Y, Kitamura S, Homma A, et al. Efficacy and safety of memantine in patients with moderate-to-severe Alzheimer’s disease: results of a pooled analysis of two randomized, double-blind, placebo-controlled trials in Japan. Expert Opin Pharmacother. 2014;15(7):913–925. doi: 10.1517/14656566.2014.902446
   PubMed Web of Science ®Google Scholar
• Czarnecka K, Chuchmacz J, Wójtowicz P, et al. Memantine in neurological disorders-schizophrenia and depression. J Mol Med (Berl). 2021;99(3):327–334.
   PubMed Web of Science ®Google Scholar
• Liu Y, Wang Q. Advances in neuroprotective strategies targeting excitotoxicity mechanisms. J Apoplexy Nervous Disease. 2019;36(6):568–570. doi: 10.19845/j.cnki.zfysjjbzz.2019.06.025
   Google Scholar
• Iasevoli F, Buonaguro EF, Sarappa C, et al. Regulation of postsynaptic plasticity genes’ expression and topography by sustained dopamine perturbation and modulation by acute memantine: relevance to schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2014;3(54):299–314. doi: 10.1016/j.pnpbp.2014.07.003
   Google Scholar
• Sato K, Mano T, Iwata A, et al. Safety of memantine in combination with potentially interactive drugs in the real world: a pharmacovigilance study using the Japanese adverse drug event report (JADER) database. J Alzheimers Dis. 2021;82(3):1333–1344. doi: 10.3233/JAD-210524
   PubMed Web of Science ®Google Scholar
• Shimoyama T, Aoki Y, Kaneda M, et al. Effects of Yokukansankachimpihange on memantine-induced dizziness in mice with memory impairment. Yakugaku Zasshi. 2021;141(7):955–960. doi: 10.1248/yakushi.21-00003
   PubMed Web of Science ®Google Scholar
• Duan J, Lao C, Chen J, et al. Memantine induces manic episode in a 73-year-old patient with vascular neurocognitive disorder: a case report. Neuropsychiatr Dis Treat. 2018;14:1395–1398. doi: 10.2147/NDT.S160832
   PubMed Web of Science ®Google Scholar
• Park DY, Kim M, Bae Y, et al. Risk of dementia in newly diagnosed glaucoma: a nationwide cohort study in Korea. Ophthalmol. 2023 Jul;130(7):684–691. Epub 2023 Feb 21. PMID: 36822436. doi: 10.1016/j.ophtha.2023.02.017
   PubMed Web of Science ®Google Scholar
• Wostyn P, Van Dam D, De Deyn PP. Alzheimer’s disease and glaucoma: look-alike neurodegenerative diseases. Alzheimers Dement. 2019;15(4):600–601. doi: 10.1016/j.jalz.2018.12.012
   PubMed Web of Science ®Google Scholar
• Cui L, Yang F, Li X, et al. A multicenter observation on the effect of Bujingyishi tablets on improving the visual function of glaucoma after intraocular pressure control. J Chin Ophthalmol Otorhinolaryngol. 2022;12(2):69–73.
   Google Scholar
• Qin Y, Wei H. Research progress on glaucoma therapeutic drugs. Drugs Clinic. 2022;37(6):1403–1408.
   Google Scholar
• Murgai AA, LeDoux MS. Memantine-induced myoclonus in a patient with Alzheimer disease. Tremor Other Hyperkinet Mov (N Y). 2015;5:337. doi: 10.5334/tohm.256
   PubMedGoogle Scholar
• Papageorgiou SG, Kontaxis T, Antelli A, et al. Exacerbation of myoclonus by memantine in a patient with Alzheimer disease. J Clin Psychopharmacol. 2007;27(4):407–408. doi: 10.1097/01.jcp.0000264995.31771.05
   PubMed Web of Science ®Google Scholar
• Moellentin D, Picone C, Leadbetter E. Memantine-induced myoclonus and delirium exacerbated by trimethoprim. Ann Pharmacother. 2008;42(3):443–447. doi: 10.1345/aph.1K619
   PubMed Web of Science ®Google Scholar
• Gallini A, Sommet A, Montastruc JL. French PharmacoVigilance Network. Does memantine induce bradycardia? A study in the French PharmacoVigilance database. Pharmacoepidemiol Drug Saf. 2008;17(9):877–881. doi: 10.1002/pds.1620
   PubMed Web of Science ®Google Scholar
• Mousailidis G, Bhan‐Kotwal S, Lazzari C, et al. Memantine‐induced bradycardia–a rare adverse reaction. Prog Neurol Psychiatry. 2018;22(1):15–18.
   Google Scholar
• Wilkinson D, C FN, Barkhof F, et al. Memantine and brain atrophy in Alzheimer’s disease: a 1-year randomized controlled trial. J Alzheimers Dis. 2012;29(2):459–469. doi: 10.3233/JAD-2011-111616
   PubMed Web of Science ®Google Scholar
• Nguyen TT, Baker B, Ferguson JD. Allergic reaction to ketamine as monotherapy for procedural sedation. J Emerg Med. 2017;52(4):562–564. doi: 10.1016/j.jemermed.2016.09.020
   PubMed Web of Science ®Google Scholar
• Mancano MA. ISMP adverse drug reactions: propofol-related infusion syndrome (PRIS)1,2; ivermectin-induced Stevens-Johnson syndrome; Stevens-Johnson syndrome/toxic epidermal necrolysis from fexofenadine; memantine-related drug Eruption. Hosp Pharm. 2018;53(4):220–222. doi: 10.1177/0018578718776857
   PubMedGoogle Scholar
• Zhang CY, He FF, Su H, et al. Association between chronic kidney disease and Alzheimer’s disease: an update. Metab Brain Dis. 2020;35(6):883–894. doi: 10.1007/s11011-020-00561-y
   PubMed Web of Science ®Google Scholar
• Ahmed AS, Elgharabawy RM, Al-Najjar AH. Ameliorating effect of anti-Alzheimer’s drugs on the bidirectional association between type 2 diabetes mellitus and Alzheimer’s disease. Exp Biol Med (Maywood). 2017;242(13):1335–1344. doi: 10.1177/1535370217711440
   PubMed Web of Science ®Google Scholar
• Luo A, Yan J, Tang X, et al. Postoperative cognitive dysfunction in the aged: the collision of neuroinflammaging with perioperative neuroinflammation. Inflammopharmacology. 2019;27(1):27–37. doi: 10.1007/s10787-018-00559-0
   PubMed Web of Science ®Google Scholar
• Iwanami J, Mogi M, Tsukuda K, et al. Possible synergistic effect of direct angiotensin II type 2 receptor stimulation by compound 21 with memantine on prevention of cognitive decline in type 2 diabetic mice. Eur J Pharmacol. 2014;724:9–15. doi: 10.1016/j.ejphar.2013.12.015
   PubMed Web of Science ®Google Scholar
• Hogan-Cann AD, Anderson CM. Physiological roles of non-neuronal NMDA receptors. Trends Pharmacol Sci. 2016;37(9):750–767. doi: 10.1016/j.tips.2016.05.012
   PubMed Web of Science ®Google Scholar
• Liao Z, Li ZS, Lu Y, et al. Glutamate receptors within the nucleus of solitary tract contribute to pancreatic secretion stimulated by intraduodenal hypertonic saline. Auton Neurosci. 2005;120(1–2):62–67. doi: 10.1016/j.autneu.2005.04.003
   PubMed Web of Science ®Google Scholar
• Choudhary AK. Aspartame: should individuals with type II diabetes be taking it? Curr Diabetes Rev. 2018;14(4):350–362. doi: 10.2174/1573399813666170601093336
   PubMed Web of Science ®Google Scholar
• Rao N, Chou T, Ventura D, et al. Investigation of the pharmacokinetic and pharmacodynamic interactions between memantine and glyburide/metformin in healthy young subjects: a single-center, multiple-dose, open-label study. Clin Ther. 2005;27(10):1596–1606. doi: 10.1016/j.clinthera.2005.10.006
   PubMed Web of Science ®Google Scholar
• Müller F, Weitz D, Derdau V, et al. Contribution of MATE1 to renal secretion of the NMDA receptor antagonist memantine. Mol Pharm. 2017;14(9):2991–2998. doi: 10.1021/acs.molpharmaceut.7b00179
   PubMedGoogle Scholar
• Klement J, Pais I, Strube J, et al. NMDA receptor blockade by memantine does not prevent adaptation to recurrent hypoglycaemia in healthy men. Diab Obes Metab. 2013;15(4):310–315. doi: 10.1111/dom.12027
   PubMed Web of Science ®Google Scholar
• Pais I, Hubold C, Hallschmid M, et al. Blocking NMDA receptor signaling does not decrease hormonal counterregulation to hypoglycemia in humans. Psychoneuroendocrinology. 2008;33(8):1069–1076. doi: 10.1016/j.psyneuen.2008.04.002
   PubMed Web of Science ®Google Scholar
• Huang XT, Yang JX, Wang Z, et al. Activation of N-methyl-D-aspartate receptor regulates insulin sensitivity and lipid metabolism. Theranostics. 2021;11(5):2247–2262. doi: 10.7150/thno.51666
   PubMed Web of Science ®Google Scholar
• Pei LJ, Tianzhi IL, Lim WS. Memantine-induced myoclonus precipitated by renal impairment and drug interactions. J Am Geriatr Soc. 2015;63(12):2643–2644. doi: 10.1111/jgs.13847
   PubMed Web of Science ®Google Scholar